ArticleInternational journal of nanomedicine2018

Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy.

You Ke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.